Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Transplantation Proceedings|September 15, 2012
Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skinL Caroti, M Zanazzi, N Paudice, et al.
Transplantation Proceedings|September 27, 2005
Homocysteine-lowering therapy and carotid intima-media thickness in renal transplant recipientsR Marcucci, M Zanazzi, E Bertoni, et al.
Clinical Nephrology|May 16, 2000
Mycophenolate mofetil (MMF) in the treatment of chronic renal rejectionL Di Maria, E Bertoni, A Rosati, et al.
Transplantation Proceedings|September 27, 2005
Venous thromboembolism in renal transplant recipients: high rate of recurrenceM Zanazzi, D Poli, E Antonucci, et al.
Transplantation Proceedings|September 27, 2005
The treatment of fistulae and ureteral stenosis after kidney transplantationV Li Marzi, M T Filocamo, E Dattolo, et al.
Transplantation Proceedings|August 19, 2007
Disseminated Scedosporium apiospermum infection in renal transplant recipient: long-term successful treatment with voriconazole: a case reportP G Rogasi, M Zanazzi, J Nocentini, et al.
Transplantation Proceedings|June 11, 2010
Reticulated platelets and platelet reactivity in renal transplant recipients receiving antiplatelet therapyM Zanazzi, F Cesari, G Rosso, et al.
Transplantation Proceedings|June 11, 2010
Lower homocysteine levels in renal transplant recipients treated with everolimus: a possible link with a decreased cardiovascular risk?S Farsetti, M Zanazzi, L Caroti, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|December 9, 2000
Risk factors for cardiovascular disease in renal transplant recipients: new insightsR Marcucci, M Zanazzi, E Bertoni, et al.
Transplantation Proceedings|June 11, 2010
Blood rheology and renal transplantation: an intriguing relationship for assessing cardiovascular riskM Zanazzi, C Fatini, S Farsetti, et al.
Pageof 4